Ipsen, Servier Advance Lung Cancer Drug After Posting Encouraging Data
Executive Summary
Liposomal chemotherapy drug Onivyde achieved a 44% response rate in second-line small cell lung cancer patients, providing preliminary validation of its ability to improve outcomes in the hard-to-treat disease.